GNL Gut and Liver
  1. Roberta D'Ambrosio, Elisabetta Degasperi, Pietro Lampertico. Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals. JHC 2021;Volume 8:713
    https://doi.org/10.2147/JHC.S292139
  2. Chang Hun Lee, In Hee Kim. Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C. Gut and Liver 2021;15:327
    https://doi.org/10.5009/gnl210191
  3. Yu-Syuan Chen, Kuo-Hsuan Huang, Pei-Ming Wang, Ching-Hui Chuang, Chee-Chien Yong, Yueh-Wei Liu, Pao-Yuan Huang, Chih-Chien Yao, Yen-Po Lin, Ming-Chao Tsai. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma. Medicina 2022;58:259
    https://doi.org/10.3390/medicina58020259
  4. Ifrah Fatima, Neehar D. Parikh, Alisa Likhitsup. Controversies of Direct-Acting Antivirals in Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2024;33:43
    https://doi.org/10.1016/j.soc.2023.06.007
© 2023. Gut and Liver. / Powered by INFOrang Co., Ltd